The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AERPIO PHARMACEUTICALS INC COM 00810B105 676 400,000 SH   DFND 1 400,000 0 0
ATEA PHARMACEUTICALS INC COM 04683R106 27,186 1,265,631 SH   DFND 1 1,265,631 0 0
IDERA PHARMACEUTICALS INC COM PAR 45168K405 68 56,250 SH   DFND 1 56,250 0 0
GENOCEA BIOSCIENCES INC COM NEW 372427401 878 375,000 SH   DFND 1 375,000 0 0
NABRIVA THERAPEUTICS PLC SHS G63637113 62 45,849 SH   DFND 1 45,849 0 0
PULMONX CORP COM 745848101 199 4,521 SH   DFND 1 4,521 0 0
SYNLOGIC INC COM 87166L100 801 205,906 SH   DFND 1 205,906 0 0